CompletedPhase 1

Continued Access to RXDX-105

United States3 participantsStarted 2018-12-14

Plain-language summary

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01): Exclusion Criteria: * Any patients other than those described above are excluded.

What they're measuring

Evaluation during treatment/intervention

Timeframe: Through study completion, up to five years.

Trial details

NCT IDNCT03784378

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-09-30

View on ClinicalTrials.gov More Non Small Cell Lung Cancer trials